Related Experiment Video
Updated: Nov 8, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Interplay Between Microglia and Alzheimer's Disease-Focus on the Most Relevant Risks: APOE Genotype, Sex and Age
Yanting Chen1, Tingting Hong1, Feng Chen1
1Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Department of Neurology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Abstract:
As the main immune cells of the central nervous system (CNS), microglia regulates normal development, homeostasis and general brain physiology. These functions put microglia at the forefront of CNS repair and recovery. Uncontrolled activation of microglia is related to the course of neurodegenerative diseases such as Alzheimer's disease. It is clear that the classic pathologies of amyloid β (Aβ) and Tau are usually accompanied by the activation of microglia, and the activation of microglia also serves as an early event in the pathogenesis of AD. Therefore, during the occurrence and development of AD, the key susceptibility factors for AD-apolipoprotein E (APOE) genotype, sex and age-may further interact with microglia to exacerbate neurodegeneration. In this review, we discuss the role of microglia in the progression of AD related to the three risk factors for AD: APOE genotype, sex and aging. APOE-expressing microglia accumulates around Aβ plaques, and the presence of APOE4 may disrupt the phagocytosis of Aβ aggregates and aggravate neurodegeneration in Tau disease models. In addition, females have a high incidence of AD, and normal female microglia and estrogen have protective effects under normal conditions. However, under the influence of AD, female microglia seem to lose their protective effect and instead accelerate the course of AD. Aging, another major risk factor, may increase the sensitivity of microglia, leading to the exacerbation of microglial dysfunction in elderly AD. Obviously, in the role of microglia in AD, the three main risk factors of APOE, sex, and aging are not independent and have synergistic effects that contribute to the risk of AD. Moreover, new microglia can replace dysfunctional microglia after microglial depletion, which is a new promising strategy for AD treatment.
Insights
Microglia, the brain's immune cells, play a critical role in Alzheimer's disease (AD) progression. Key risk factors like APOE genotype, sex, and aging interact with microglia, exacerbating neurodegeneration and offering potential therapeutic targets.
Area of Science:
- Neuroscience and Immunology
- Central Nervous System (CNS) Immune Cell Function
- Neurodegenerative Disease Pathogenesis
Background:
- Microglia are essential for CNS homeostasis, development, and repair.
- Dysregulated microglial activation is implicated in neurodegenerative diseases, notably Alzheimer's disease (AD).
- Classic AD pathologies, amyloid-beta (Aβ) and Tau, are associated with microglial activation, an early pathogenic event.
Purpose of the Study:
- To review the role of microglia in AD progression.
- To examine the interaction between microglia and major AD risk factors: apolipoprotein E (APOE) genotype, sex, and aging.
- To explore potential therapeutic strategies targeting microglial dysfunction in AD.
Main Methods:
- Literature review focusing on microglial function in AD.
- Analysis of studies investigating the influence of APOE genotype, sex, and aging on microglial activity in AD models.
- Synthesis of current understanding of microglial involvement in AD pathogenesis.
Main Results:
- APOE genotype, particularly APOE4, influences microglial Aβ clearance and can exacerbate Tau pathology.
- Female microglia, protective under normal conditions, may accelerate AD progression in the disease state.
- Aging increases microglial sensitivity, potentially worsening microglial dysfunction and AD severity.
Conclusions:
- APOE genotype, sex, and aging synergistically interact with microglia to increase AD risk and progression.
- Microglial dysfunction is a central component in AD pathogenesis driven by these risk factors.
- Microglial depletion and replacement represent a promising therapeutic avenue for AD treatment.
More Related Videos
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment